Viasat to Participate in Two Upcoming Investor Conferences
Get Alerts VSAT Hot Sheet
Join SI Premium – FREE
CARLSBAD, Calif., Feb. 25, 2019 /PRNewswire/ -- Viasat Inc. (NASDAQ: VSAT), a global communications company, announced today that Mark Dankberg, Viasat's chairman and CEO, will present at the following upcoming investor conferences:
- Morgan Stanley Technology, Media & Telecom Conference on February 26, 2019, at 1:30pm Pacific Time, in San Francisco, Calif.
- Raymond James 40th Annual Institutional Investor Conference on March 5, 2019, at 9:15am Eastern Time in Orlando, Fl.
The presentations and/or webcasts will be available at the investor relations section of Viasat's corporate website at: investors.viasat.com.
About ViasatViasat is a global communications company that believes everyone and everything in the world can be connected. For more than 30 years, Viasat has helped shape how consumers, businesses, governments and militaries around the world communicate. Today, the Company is developing the ultimate global communications network to power high-quality, secure, affordable, fast connections to impact people's lives anywhere they are—on the ground, in the air or at sea. To learn more about Viasat, visit: www.viasat.com, go to Viasat's Corporate Blog, or follow the Company on social media at: Facebook, Instagram, LinkedIn, Twitter or YouTube.
Copyright © 2019 Viasat, Inc. All rights reserved. All other product or company names mentioned are used for identification purposes only and may be trademarks of their respective owners. Viasat is a registered trademark of Viasat, Inc.
View original content:http://www.prnewswire.com/news-releases/viasat-to-participate-in-two-upcoming-investor-conferences-300801414.html
SOURCE Viasat, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advantech Unveils Qualcomm® Dragonwing™ IQ9-Based Solutions for Industrial Vision Intelligence
- Consortium launches cross-regional pilot on post-quantum security with participation from banks and regulatory stakeholders
- Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Raymond James, Morgan Stanley, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share